Abstracts tagged "Inflammation"

Abstract Number: 0090 • ACR Convergence 2021
Subcutaneous Sarilumab in Hospitalized Patients with Moderate-severe COVID-19 Infection Compared to the Standard Care: An Open-label Randomized Clinical Trial
Sebastián C Rodriguez-García¹, Isidoro Gonzalez-Alvaro¹, Francisco Abad-Santos², Azucena Bautista-Hernández³, Lucio García-Fraile³, Juan Pablo Baldivieso-Achá⁴, Jesús Sanz-Sanz³ and Rosario Garcia de Vicuña¹, ¹Rheumatology Service. La Princesa University Hospital, Madrid, Spain, ²Clinical Pharmacology Service. Clinical Research and Clinical Trials Unit. La Princesa University Hospital, Madrid, Spain, ³Division of Infectious Diseases, Internal Medicine Service. La Princesa University Hospital, Madrid, Spain, ⁴Rheumatology Department. La Princesa University Hospital, Madrid, Spain
Background/Purpose: Many uncertainties remain for IL-6 blockers on the management of COVID-19 such as the optimal time of intervention, the schedule of administration and predictors…
Abstract Number: 0541 • ACR Convergence 2021
N-formyl Methionine Peptide-mediated Neutrophil Activation in Systemic Sclerosis
Runa Kuley¹, Ryan Stultz², Bhargavi Duvvuri², Roger Hesselstrand³, J Lee Nelson⁴ and Christian Lood², ¹Division of Rheumatology, University of Washington, Seattle, WA, ²University of Washington, Seattle, WA, ³Lund University, Lund, Sweden, ⁴Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA
Background/Purpose: Systemic sclerosis (SSc) is a complex systemic autoimmune disease, and its etiology is unknown. Exaggerated neutrophil activation and formation of neutrophil extracellular traps (NETs)…
Abstract Number: 1016 • ACR Convergence 2021
Assessment of Pre-Inflammatory Mesenchymal (PRIME) Cells as a Biomarker of Tumor Necrosis Factor-Induced Arthritis in Mice
Kiana Chen¹, Xi Lin¹, Lianping Xing², H. Mark Kenney³, Richard Bell⁴, Edward Schwarz⁵ and Homaira Rahimi⁵, ¹University of Rochester School of Medicine and Dentistry, Rochester, NY, ²University of Rochester Medical Center, Webster, NY, ³University of Rochester Medical Center, Rochester, NY, ⁴Hospital for Special Surgery, New York, NY, ⁵University of Rochester, Rochester, NY
Background/Purpose: Recently, CD45−CD31−Podoplanin (PDPN)+ synovial fibroblast-like cells, termed pre-inflammatory mesenchymal (PRIME) cells were found to be differentially expressed and circulate in the blood of rheumatoid…
Abstract Number: 1454 • ACR Convergence 2021
RHAPSODY: Rilonacept, an IL-1α and IL-1β Trap, Resolves Pericarditis Episodes and Reduces Risk of Recurrence in a Phase 3 Trial of Patients with Recurrent Pericarditis
Allan Klein¹, Massimo Imazio², Paul Cremer¹, Antonio Brucato³, Antonio Abbate⁴, Fang Fang⁵, Antonella Insalaco⁶, Martin LeWinter⁷, Basil S. Lewis⁸, David Lin⁹, Sushil A. Luis¹⁰, Stephen J. Nicholls¹¹, Arian Pano⁵, Alistair Wheeler¹², Liangxing Zou⁵ and John F Paolini⁵, ¹Department of Cardiovascular Imaging, Center for the Diagnosis and Treatment of Pericardial Diseases, Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH, ²University Cardiology, Cardiovascular and Thoracic Department, AOU Città della Salute e della Scienza di Torino, Torino, Italy, ³Department of Biomedical and Clinical Science, University of Milano, Fatebenefratelli Hospital, Milan, Italy, ⁴VCU Pauley Heart Center, Virginia Commonwealth University, Richmond, VA, ⁵Kiniksa Pharmaceuticals Corp., Lexington, MA, ⁶Department of Pediatric Medicine, Division of Rheumatology, Bambino Gesù Children's Hospital, Rome, Italy, ⁷Cardiology Unit, The University of Vermont Medical Center, The University of Vermont, Burlington, VT, ⁸Cardiovascular Clinical Research Institute, Lady Davis Carmel Medical Center, Haifa, Israel, ⁹Minneapolis Heart Institute at Abbott Northwestern Hospital, Minneapolis, MN, ¹⁰Division of Cardiovascular Ultrasound, Department of Cardiovascular Medicine, Mayo Clinic, Rochester, NY, ¹¹MonashHeart, Department of Cardiology, Monash University, Clayton, Australia, ¹²Kiniksa Pharmaceuticals, Ltd., Hamilton, Bermuda
Background/Purpose: Recurrent pericarditis (RP) is an autoinflammatory disease with no FDA-approved therapies. RHAPSODY, a global Phase 3 study, evaluated rilonacept, a once-weekly IL-1α/IL-1β trap, in…
Abstract Number: 0162 • ACR Convergence 2021
Cardiac Magnetic Resonance Imaging for Guiding Decision-making on Treatment Duration: Data from RHAPSODY, a Phase 3 Clinical Trial of Rilonacept in Recurrent Pericarditis
Paul Cremer¹, David Lin², Alistair Wheeler³, Antonio Abbate⁴, Antonio Brucato⁵, Fang Fang⁶, Antonella Insalaco⁷, Martin LeWinter⁸, Basil S. Lewis⁹, Sushil A. Luis¹⁰, Stephen J. Nicholls¹¹, John Petersen¹², Allan Klein¹, Massimo Imazio¹³ and John F Paolini⁶, ¹Department of Cardiovascular Imaging, Center for the Diagnosis and Treatment of Pericardial Diseases, Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH, ²Minneapolis Heart Institute at Abbott Northwestern Hospital, Minneapolis, MN, ³Kiniksa Pharmaceuticals, Ltd., Hamilton, Bermuda, ⁴VCU Pauley Heart Center, Virginia Commonwealth University, Richmond, VA, ⁵Department of Biomedical and Clinical Science, University of Milano, Fatebenefratelli Hospital, Milan, Italy, ⁶Kiniksa Pharmaceuticals Corp., Lexington, MA, ⁷Department of Pediatric Medicine, Division of Rheumatology, Bambino Gesù Children's Hospital, Rome, Italy, ⁸Cardiology Unit, The University of Vermont Medical Center, The University of Vermont, Burlington, VT, ⁹Cardiovascular Clinical Research Institute, Lady Davis Carmel Medical Center, Haifa, Israel, ¹⁰Division of Cardiovascular Ultrasound, Department of Cardiovascular Medicine, Mayo Clinic, Rochester, NY, ¹¹MonashHeart, Department of Cardiology, Monash University, Clayton, Australia, ¹²Swedish Medical Center, Seattle, WA, ¹³University Cardiology, Cardiovascular and Thoracic Department, AOU Città della Salute e della Scienza di Torino, Torino, Italy
Background/Purpose: The magnitude of pericardial delayed hyperenhancement (DHE) by cardiac magnetic resonance imaging (CMR) illustrates the severity of inflammation in pericarditis. We hypothesized that patients…
Abstract Number: 0590 • ACR Convergence 2021
Association of Lipid Mediator Profiles and Development of Future Incident Inflammatory Arthritis in a High Risk, Anti-citrullinated Protein Antibody Positive Population
Lauren Vanderlinden¹, Elizabeth Bemis², Kristen Polinski³, Kristen Demoruelle⁴, Marie Feser⁵, Jennifer Seifert⁶, Ted Mikuls⁷, Michael Weisman⁸, Jane Buckner⁹, Kevin Deane¹⁰, Michael Clare-Salzler¹¹, V. Michael Holers¹² and Jill Norris¹³, ¹Colorado School of Public Health, Monument, CO, ²Colorado School of Public Health Anschutz Medical Campus, Aurora, CO, ³CSPH, Gaithersburg, CO, ⁴University of Colorado Anschutz Medical Campus, Aurora, CO, ⁵University of Colorado Denver, Aurora, CO, ⁶University of Colorado School of Medicine, Littleton, CO, ⁷University of Nebraska Medical Center, Omaha, NE, ⁸Adjunct Professor of Medicine, Stanford University; Distinguished Professor of Medicine Emeritus, David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁹Benaroya Research Institute at Virginia Mason, Seattle, WA, ¹⁰University of Colorado Denver, Denver, CO, ¹¹Department of Pathology, Immunology and Laboratory Medicine, University of Florida College of Medicine, Gainesville, FL, ¹²University of Colorado, Denver, CO, ¹³Colorado School of Public Health, Aurora, CO
Background/Purpose: Lipid mediators are endogenously derived from the metabolism of omega-3 and omega-6 polyunsaturated fatty acids (PUFAs) and have important roles in promoting and resolving…
Abstract Number: 1045 • ACR Convergence 2021
Composition of Phospholipid Fatty Acids in Erythrocyte Membranes from Patients with Ankylosing Spondylitis
Junming Chen, Xuechan Huang, Qidang Huang, Zhixiang Huang, Yukai Huang, Yuqi Liu, Lixin Huang, Shanmiao Sun, Zhuyi ji and Tianwang Li, Guangdong Second Provincial General Hospital, Guangzhou, China (People's Republic)
Background/Purpose: To investigate the composition of phospholipid fatty acids in erythrocyte membranes from patients with ankylosing spondylitis (AS), and determine the correlations between the percentage…
Abstract Number: 1455 • ACR Convergence 2021
IL1β mRNA Expressions in Peripheral Blood Mononuclear Cells Increase and May Associate with Cartilage Damage of the Respiratory Tract Probably Through Matrix metalloproteinase-3 Production in Patients with Relapsing Polychondritis
Jun Shimizu¹, Sueshige Wakisaka¹, Tomoko Suzuki¹ and Noboru Suzuki², ¹St. Marianna University School of Medicine, Kawasaki, Japan, ²St. Marianna University School of Medicine, Kawasaki Kanagawa, Japan
Background/Purpose: Relapsing polychondritis (RP) is an inflammatory disorder that affects cartilage of ears, nose, joints, and respiratory tract. The inflammation often spreads to eyes, cardiovascular…
Abstract Number: 0185 • ACR Convergence 2021
Phase 1 Study Results of GS-5718, an Oral IRAK4-Inhibitor: Pharmacodynamics of Single and Multiple Doses of GS-5718 in Healthy Subjects
Silke Roedder¹, Emily Wendt², Chad Burris², Jonathan Nazareon², Grace Park³, Phil Pangilinan², Gianna Huang², Anubhav Mathur², James Taylor², Andrew Billin² and Franziska Matzkies⁴, ¹Gilead Sciences, Menlo Park, CA, ²Gilead Sciences, Foster City, CA, ³Gilead Sciences, Seattle, WA, ⁴Gilead Sciences, Inc., Foster City, CA
Background/Purpose: Adaptive and innate immune pathways are involved in inflammation and pathogenesis of autoimmune diseases including Rheumatoid Arthritis (RA) and Lupus Erythematosus (LE). Immune complexes…
Abstract Number: 0677 • ACR Convergence 2021
Pro-Inflammatory Diet and Increased Risk of Incident Female Gout: 30-Year Prospective Cohort Study of >170,000 Pre- and Post-Menopausal US Women
Natalie McCormick¹, Chio Yokose², Na Lu³, Amit Joshi¹ and Hyon K. Choi⁴, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Waltham, MA, ³Arthritis Research Canada, Vancouver, BC, Canada, ⁴Massachusetts General Hospital, Lexington, MA
Background/Purpose: Globally, the prevalence of gout is rising in females more than males,1 but data on modifiable risk factors for female gout are scarce. Emerging…
Abstract Number: 1086 • ACR Convergence 2021
Lack of Effect of SARS-CoV-2 Vaccination on Cell Bound Complement Activation Products (CB-CAPs), Multianalyte Assay Panel (MAP) with Algorithm, and Inflammatory Biomarkers
Mark Rudolph, Anja Kammensheidt and Roberta Alexander, Exagen Inc., Vista, CA
Background/Purpose: SARS-CoV-2 infection can lead to severe inflammation including increased complement activation (Ma, Kulkarni 2021) and the production of several proinflammatory cytokines. The rapid deployment…
Abstract Number: 1498 • ACR Convergence 2021
Platelet Secreted LGALS3BP Induces a Pro-inflammatory Phenotype in Systemic Lupus Erythematosus
Hanane EL Bannoudi¹, MacIntosh Cornwell², Elliot Luttrell-Williams², Alexis Engel³, Christina Rolling¹, Peter Izmirly⁴, H. Michael Belmont⁵, Kelly Ruggles², Robert Clancy⁶, Jill Buyon⁵ and Jeffrey Berger², ¹NYU Langone Health, New York, NY, ²New York University, New York, NY, ³NYU Langone Health, New Yok, NY, ⁴New York University School of Medicine, New York, NY, ⁵NYU School of Medicine, New York, NY, ⁶NYU Grossman School of Medicine, New York, NY
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a complex chronic heterogeneous autoimmune disease, which increases the risk of atherothrombosis. In addition to their well described role…
Abstract Number: 0189 • ACR Convergence 2021
Tapering and Discontinuation of Background Therapies During the Transition to Rilonacept Monotherapy in RHAPSODY, a Phase 3 Clinical Trial of Rilonacept in Patients with Recurrent Pericarditis
Antonio Brucato¹, Alistair Wheeler², Sushil A. Luis³, Antonio Abbate⁴, Paul Cremer⁵, Fang Fang⁶, Antonella Insalaco⁷, Martin LeWinter⁸, Basil S. Lewis⁹, David Lin¹⁰, Stephen J. Nicholls¹¹, Allan Klein⁵, Massimo Imazio¹² and John F Paolini⁶, ¹Department of Biomedical and Clinical Science, University of Milano, Fatebenefratelli Hospital, Milan, Italy, ²Kiniksa Pharmaceuticals, Ltd., Hamilton, Bermuda, ³Division of Cardiovascular Ultrasound, Department of Cardiovascular Medicine, Mayo Clinic, Rochester, NY, ⁴VCU Pauley Heart Center, Virginia Commonwealth University, Richmond, VA, ⁵Department of Cardiovascular Imaging, Center for the Diagnosis and Treatment of Pericardial Diseases, Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH, ⁶Kiniksa Pharmaceuticals Corp., Lexington, MA, ⁷Department of Pediatric Medicine, Division of Rheumatology, Bambino Gesù Children's Hospital, Rome, Italy, ⁸Cardiology Unit, The University of Vermont Medical Center, The University of Vermont, Burlington, VT, ⁹Cardiovascular Clinical Research Institute, Lady Davis Carmel Medical Center, Haifa, Israel, ¹⁰Minneapolis Heart Institute at Abbott Northwestern Hospital, Minneapolis, MN, ¹¹MonashHeart, Department of Cardiology, Monash University, Clayton, Australia, ¹²University Cardiology, Cardiovascular and Thoracic Department, AOU Città della Salute e della Scienza di Torino, Torino, Italy
Background/Purpose: Post-episode tapering of Standard of Care (SoC) medication in patients with recurrent pericarditis (RP) varies considerably. Gradual tapering of corticosteroids (CS) is recommended in…
Abstract Number: 0694 • ACR Convergence 2021
Glucagon-like Peptide-1 Receptor Agonist Suppresses Muscle Fiber Necroptosis and Muscle Inflammation and Ameliorates Muscle Weakness in Experimental Polymyositis
Mari Kamiya¹, Fumitaka Mizoguchi¹, Hirokazu Sasaki², Natsuka Umezawa¹ and Shinsuke Yasuda³, ¹Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Japan, ²Department of Lifetime Clinical Immunology, Graduate School of Medical and Dental Science, Tokyo Medical and Dental University (TMDU), Tokyo, Japan, ³Tokyo Medical and Dental University (TMDU), Tokyo, Japan
Background/Purpose: While glucocorticoids (GC) are the cornerstone of the treatment for polymyositis (PM), GC-induced myopathy is inevitable, which deteriorates muscle weakness. Therefore, novel therapeutic strategy…
Abstract Number: 1110 • ACR Convergence 2021
Cryopyrin-associated Periodic Syndromes: GOSH and National Amyloidosis Centre Experience
Ovgu Kul Cinar¹, Charalampia Papadopoulou², Amber Putland¹, Karen Wynne¹, Helen J Lachmann³, Despina Eleftheriou⁴ and Paul A. Brogan⁴, ¹Great Ormond Street Hospital NHS Trust, London, United Kingdom, ²UCL Institute of Child Health, and Great Ormond Street Hospital NHS Foundation Trust, Infection, Immunology, and Rheumatology, London, United Kingdom, ³National Amyloidosis Centre, Royal Free Campus, UCL Medical School, London, United Kingdom, ⁴Great Ormond Street Hospital NHS Trust, UCL GOS Institute of Child Health, Department of Infection, Immunity & Inflammation, London, United Kingdom
Background/Purpose: CAPS is a rare, heterogenous inflammasomopathy associated with gain-of-function mutations in NLRP3 that encodes cryopyrin. Mutations in NLRP3 result in excessive IL-1ß production that…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].